Verified peer comparison

ABT vs ISRG

Abbott Laboratories compared with Intuitive Surgical, Inc.. This page compares both source-verified company profiles and does not introduce an unverified price target.

ABT

Abbott Laboratories

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

ISRG

Intuitive Surgical, Inc.

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

Company-specific comparison

Business exposure

ABT: Health Care Equipment

ISRG: Health Care Equipment

Upside lens

ABT: Broad growth across Abbott's medical-device portfolio, including diabetes care and structural heart, can remain the company's primary organic growth engine. The Exact Sciences acquisition establishes a meaningful oncology-diagnostics platform and adds long-term growth opportunities in cancer screening and precision diagnostics. Continued growth in key emerging markets can provide a diversified contribution from established branded generics.

ISRG: Continued da Vinci and Ion procedure growth increases utilization and expands recurring instruments, accessories, and service demand. Growing da Vinci 5 placements can refresh the installed base, deepen customer adoption, and support higher system and recurring revenue over time. Expansion of the da Vinci and Ion installed bases increases the platform available for future procedures, services, and instruments and accessories revenue.

Risk lens

ABT: Nutrition sales declined in the quarter, and persistent weakness could offset strength in medical devices and established pharmaceuticals. The large Exact Sciences transaction introduces integration, financing, dilution, and execution risks before projected strategic benefits are realized. Ongoing preterm infant formula litigation creates uncertain legal costs and potential reputational pressure for the nutrition business.

ISRG: Tariffs are expected to reduce gross margin, and additional measures beyond those assumed in guidance could have a material financial effect. New systems and indications require regulatory clearances, while expanding robotic-surgery competition could pressure placements, pricing, or utilization. A large share of systems placed under operating leases increases exposure to customer utilization and can delay revenue recognition relative to outright sales.

Verified sources

Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact SciencesAbbott Laboratories · earningsVerified